

Published in final edited form as:


Org Lett. 2006 June 8; 8(12): 2575–2578. doi:10.1021/ol060773d.

Synthesis and Evaluation of Fluorogenic Substrates for Phospholipase D and Phospholipase C

Tyler M. Rose and Glenn D. Prestwich*

Department of Medicinal Chemistry, University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, UT 84108

Abstract



Fluorogenic analogues of phosphatidylcholine and lysophosphatidylcholine, DDPB and lysoDDPB, were synthesized by an enzyme-assisted strategy. The analogues were evaluated as substrates for phospholipases C and D, and lysophospholipase D. DDPB was cleaved by bacterial and plant phospholipase D (PLD) enzymes and represents the first direct fluorogenic substrate for real-time measurement of PLD activity. Both fluorogenic substrates have potential in screening for PLD and PC-PLC inhibitors, and for monitoring spatiotemporal changes in PLD activity in cells.

PLC, PLD, and lysoPLD are three phospholipases that catalyze hydrolysis of phospholipid (PL) head groups. PLC catalyzes the hydrolysis of the PL phosphodiester glyceryl P-O bond to give diacylglycerol and a phosphomonoester. PLD cleaves the head group P-O bond of the phosphodiester linkage, to produce phosphatidic acid (PA) and an alcohol. LysoPLD catalyzes the same reaction as PLD, but is selective for lysophospholipids. Most PLDs also catalyze transphosphatidylation,¹ in which a primary alcohol replaces water as the cleaving nucleophile.

PLC isozymes selectively hydrolyze PLs with either inositol or choline headgroups. There are at least eleven different phosphoinositide-selective PLCs (PI-PLC),² two putative phosphatidylcholine-selective PLCs (PC-PLCs)³ in mammals, and one PC-PLC in plants.⁴

PLD isozymes found in mammals are involved in a diversity of normal and disease-related biological processes.^{5–7} The PLD enzymes found in mammals, plants, and some bacteria are called “HKD PLD” because they share a consensus amino acid sequence (HxKx₄Dx₆GG/S), and employ a common catalytic mechanism involving a covalent histidine intermediate.⁸ The “non-HKD PLD” enzymes lack an HKD consensus sequence, and have a catalytic mechanism in which metal ions are required to position the PL substrate and activate the attacking nucleophile.⁹ *S. chromofuscus* PLD (scPLD) is an archetypical non-HKD PLD. Similar to the

non-HKD PLD, lysoPLD requires metal ions for catalysis and does not contain an HKD sequence.¹⁰ The lysoPLD autotaxin, a nucleotide pyrophosphatase/phosphodiesterase, catalyzes hydrolysis via an active site threonine.¹¹

HKD PLDs can be detected in cell biological studies by inhibition with exogenous ethanol, 1-propanol, or 1-butanol. Biochemical assays employ radioactive¹² or fluorescent¹³ PLs, requiring extraction, separation, and detection. Alternatively, PLD products can be detected *in vitro* using direct¹⁴ or indirect^{15–18} methods. There are also indirect assays for PC-PLC^{18, 19} and lysoPLD;²⁰ in particular, *p*-nitrophenylphosphate analogues have also been used for monitoring non-HKD PLD and lysoPLD,^{21, 22} and PC-PLC²³ *in vitro*. Fluorogenic substrates for lysoPLD have recently been described.^{24,25}

We report here the synthesis of fluorogenic PC and lysoPC analogues that contain a fluorescence quencher (dabcyl, a.k.a *p*-methyl red) at each acyl chain terminus, and a fluorophore appended to the PL head group through a choline-mimetic linker. These PL analogues, denoted **DDPB** and **lysoDDPB**, were evaluated in microtiter plate assays as substrates for lysoPLD, scPLD, PLC, and phospholipase A₂ (PLA₂), as well as several commercially-available HKD PLD enzymes.

DDPB and **lysoDDPB** were synthesized efficiently as illustrated in Schemes 1 and 2. The lysophosphatidylcholine intermediate **2** containing the shorter dabcyl acyl chain was obtained a selective monoacylation of the commercially-available glycerol phosphocholine, **1**, followed by installation of the longer-chain dabcyl quencher at the *sn*-2 position (**4**, Scheme 1). While the longer, dodecanoyl acyl chain at *sn*-2 improved the lipophilicity of the analogue over compounds with two hexanoyl chains, adding a second C₁₂ linker at *sn*-1 afforded a less soluble analog that did not exhibit either improved micelle insertion or *in vitro* enzyme activity (data not shown).

The key step was the modification of the head group of intermediate **4** by transphosphatidylation, using Genzyme PLD(P) and a designed “choline-like” primary alcohol **6**, prepared as shown in Scheme 2. Transphosphatidylation has been exploited previously^{26–28} to generate PL analogues with both natural and unnatural head groups. In this case, the head group remodeling allowed the installation of a phosphodiester linkage bearing an internal quaternary amine similar to choline as well as a protected primary amine that could be used for further conjugation reactions (**7**, Scheme 2). The primary amine was deprotected and allowed to react with an activated ester of BODIPY-FL (Molecular Probes) to give the fluorogenic PC analogue **DDPB** (Scheme 2). Removal of the *sn*-2 ester of **DDPB** by cobra venom PLA₂ gave **lysoDDPB**, a fluorogenic lysoPC analogue.

Mixed micelles containing **DDPB** or **lysoDDPB** in Triton X-100 (reduced) were incubated with commercial PLDs from various sources for 3 min in buffers near each enzyme’s pH optimum. Over this period, **DDPB** (Figure 1a) gave robust fluorescence increases with the enzyme used for its synthesis, Genzyme PLD(P), and with scPLD. **LysoDDPB** (Supporting information, Figure 2) over 3 min, gave a comparable signal with scPLD, but only a very small response to Genzyme PLD(P). Over 60 min (Figure 1b), **DDPB** mixed micelles with HKD PLD from peanut, cabbage, and *Streptomyces PMF* (BIOMOL) evolved fluorescence to a degree approaching that observed in 3 min with scPLD, but bee and cobra venom sPLA₂ did not generate a fluorescent signal over the same time period, consistent with the retention of an intramolecular quencher even after cleavage of the *sn*-2 quenched acyl chain. Longer incubation time with **lysoDDPB** mixed micelles (Supporting information, Figure 3) only amplified fluorescence from Genzyme PLD(P). These results support the idea that lysophospholipids are substrates for scPLD,¹⁴ but are not substrates for HKD PLD.^{29,30}

Next, mixed micelles of the PC analogues were tried as substrates for PC-PLC from *Bacillus cereus* and *Clostridium perfringens* and PI-PLC from *B. cereus* (Figure 1c). Over 3 min, **DDPB** gave an overwhelmingly large fluorescence response with *B. cereus* PC-PLC and virtually none with *B. cereus* PI-PLC or *C. perfringens* PC-PLC. **LysoDDPB** gave a small but detectable signal with *B. cereus* PC-PLC, but none with the other PLC tested.

We anticipated that **lysoDDPB** would be accepted as a fluorogenic substrate by lysoPLD, but neither **lysoDDPB**-nor **DDPB**-containing mixed micelles produced fluorescence when assayed in the presence of FBS, an abundant source of lysoPLD activity,³¹ even after 60 min incubation. On the other hand, the commercial lysoPLD substrates *p*NP-TMP³² and FS-3²⁵ both generated significant UV and fluorescence signals, respectively (Supporting information, Figure 4). **LysoDDPB** was assayed with 50% FBS at 37 °C, but no fluorescence increase was observed even when the concentration of **lysoDDPB** was quadrupled and the FBS concentration increased to 80% (data not shown). Incubation of **lysoDDPB**-containing micelles with up to 2 μ g of venom from *Loxosceles reclusa*, another known source of lysoPLD,³³ failed to show a fluorescence increase (data not shown).

The inability of lysoPLD to hydrolyze **lysoDDPB** was unexpected, considering the close structural similarity among lysoPC, **lysoDDPB** and FS-3 (Supporting information, Figure 4). The phosphate linker of FS-3, in spite of its lack of a quaternary amine, is nearly twice the length of that in **lysoDDPB**. This extra length may give the bulky fluorescent group of FS-3 flexibility to avoid unfavorable interactions in the binding site. Increasing the chain length between the phosphate and the fluorophore in future fluorogenic analogues of lysoPC could test this supposition.

DDPB and **lysoDDPB** were both designed to be PC-like, amphiphilic probes that could be used in living cells by inserting into lipid bilayers; neither is freely soluble in water. **DDPB** was further engineered to have fluorescence quenchers at the end of each acyl chain in order to prevent fluorescence increases resulting from cellular PLA₂ or PLA₁ activity. Indeed, no fluorescent signal was observed even after incubation of **DDPB** with venom PLA₂ at 37 °C for 1 hr (Figure 1c).

Given the well-established importance of the HKD PLDs and the growing importance of PC-PLC in cell signaling, **DDPB** and **lysoDDPB** have the potential to be valuable tools in cellular and molecular biology. The utility of these fluorogenic substrates with mammalian HKD PLD has been observed and will be reported elsewhere (M. Hogdkin, personal communication). Both **DDPB** and **lysoDDPB** are cell-permeant (data not shown) and may be applicable for cell-based assays, as previously described for PLA₂.^{34,35} Further studies examining the use of **DDPB** and **lysoDDPB** in living systems are merited and will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank C. Ferguson (Echelon Biosciences, Inc., an Aeterna Zentaris company), for providing a gift of FS-3. The Center for Cell Signaling, a Utah Center of Excellence (1997-2002) and the NIH (Grants HL070231 and NS29632 to GDP) provided financial support.

References

1. Yang SR, Freer S, Benson AA. J Biol Chem 1967;242:477–484. [PubMed: 6022844]
2. Bradshaw, RA.; Dennis, EA. Handbook of cell signaling. Academic Press; Amsterdam; Boston: 2004.

3. Ramoni C, Spadaro R, Menegon M, Podo F. *J Immunol* 2001;167:2642–2650. [PubMed: 11509606]
4. Nakamura Y, Awai K, Masuda T, Yoshioka Y, Takamiya K, Ohta H. *J Biol Chem* 2005;280:7469–76. [PubMed: 15618226]
5. Foster DA, Xu L. *Mol Cancer Res* 2003;1:789–800. [PubMed: 14517341]
6. Freyberg Z, Siddhanta A, Shields D. *Trends Cell Biol* 2003;13:540–546. [PubMed: 14507482]
7. Bandyopadhyay G, Sajan MP, Kanoh Y, Standaert ML, Quon MJ, Reed BC, Dikic I, Farese RV. *J Biol Chem* 2001;276:35537–35545. [PubMed: 11463795]
8. Muller, G.; Petty, S. *Lipases and phospholipases in drug development: from biochemistry to molecular pharmacology*. Wiley-VCH; Weinheim: 2004. p. xviii. 336
9. Zambonelli C, Roberts MF. *Prog Nucleic Acid Res Mol Biol* 2005;79:133–181. [PubMed: 16096028]
10. Gijbsbers R, Ceulemans H, Stalmans W, Bollen M. *J Biol Chem* 2001;276:1361–1368. [PubMed: 11027689]
11. Stefan C, Jansen S, Bollen M. *Trends Biochem Sci* 2005;30:542–550. [PubMed: 16125936]
12. Jiang X, Gutowski S, Singer WD, Sternweis PC. *Methods Enzymol* 2002;345:328–334. [PubMed: 11665616]
13. Xie Y, Meier KE. *Methods Enzymol* 2002;345:294–305. [PubMed: 11665613]
14. Mezna M, Lawrence AJ. *Anal Biochem* 1994;218:370–376. [PubMed: 8074295]
15. Kinkaid AR, Wilton DC. *Biochem Soc Trans* 1997;25:S595. [PubMed: 9450023]
16. Hergenrother PJ, Haas MK, Martin SF. *Lipids* 1997;32:783–788. [PubMed: 9252969]
17. Petersen G, Chapman KD, Hansen HS. *J Lipid Res* 2000;41:1532–1538. [PubMed: 10974061]
18. Zhou M, Zhang C, Haugland RP. *Proc SPIE* 2000;3926:166–171.
19. Wilton DC. *Biochem J* 1991;276(Pt 1):129–133. [PubMed: 1903930]
20. Umezu-Goto M, Kishi Y, Taira A, Kama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. *J Cell Biol* 2002;758:227–33. [PubMed: 12119361]
21. Gijbsbers R, Aoki J, Arai H, Bollen M. *FEES Lett* 2003;538:60–64.
22. Cha J, Lee J, Koh EH, Choi MU. *Bull Korean Chem Soc* 1994;75:1001–1003.
23. Kurioka S, Matsuda M. *Anal Biochem* 1976;75:281–289. [PubMed: 183567]
24. Takakusa H, Kikuchi K, Urano Y, Sakamoto S, Yamaguchi K, Nagano T. *J Am Chem Soc* 2002;124:1653–1657. [PubMed: 11853439]
25. Ferguson CG, Bigman CS, Richardson RD, van Meeteren LA, Moolenaar WA, Prestwich GD. *Org Lett*. 2006in press
26. D'Arrigo P, de Ferra L, Piergianni V, Selva A, Servi S, Strini A. *J Chem Soc, Perkin Trans 1* 1996;21:2651–2656.
27. Wang P, Schuster M, Wang Y-R, Wong CH. *J Am Chem Soc* 1993;115:10487–10491.
28. Pisch S, Bornscheuer UT, Meyer HH, Schmid RD. *Tetrahedron* 1991;53:14627–14634.
29. Ryu SB, Karlsson BH, Ozgen M, Palta JP. *Proc Natl Acad Set USA* 1997;94:12717–12721.
30. Ryu SB, Palta JP. *J Lipid Res* 2000;41:940–944. [PubMed: 10828086]
31. Umezu-Goto M, Kishi Y, Taka A, Kama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. *J Cell Biol* 2002;158:227–233. [PubMed: 12119361]
32. Decker K, Bischoff E. *FEES Lett* 1972;21:95–98.
33. Lee S, Lynch KR. *Biochem J* 2005;391:317–323. [PubMed: 15926888]
34. Feng L, Manabe K, Shope JC, Widmer S, DeWald DB, Prestwich GD. *Chem Biol* 2002;9:795–803. [PubMed: 12144923]
35. Rose TM, Prestwich GD. *ACS Chem Biol* 2006;1:83–91. [PubMed: 17163648]






Figure 1.

Fluorescence evolution ($\lambda_{\text{Ex}}/\lambda_{\text{Em}} = 500/530$ nm) during a) 3 min incubation of **DDPB** mixed micelles with PLD from various sources (\blacklozenge = peanut PLD; \blacksquare = cabbage PLD; \blacktriangle = *Strep. PMF* PLD; \times = Genzyme PLD(P); \circ = scPLD), b) 60 min incubation of **DDPB** mixed micelles with PLD and PLA₂ from various sources (\blacklozenge = peanut PLD; \blacksquare = cabbage PLD; \blacktriangle = *Strep. PMF* PLA₂; \times = cobra venom PLA₂; \circ = bee venom PLA₂), and c) 3 min incubation of **DDPB** or **lysoDDPB** mixed micelles with PC-PLC or PI-PLC from *B. cereus* or *C. perfringens* (\blacksquare = *B. cereus* PC-PLC + **DDPB**; \blacktriangle = *B. cereus* PC-PLC + **lysoDDPB**; \diamond = *C. perfringens* PC-PLC + **DDPB**; \bullet = *C. perfringens* PC-PLC + **lysoDDPB**; $+$ = *B. cereus* PI-PLC + **DDPB**; \blacksquare = *B. cereus* PI-PLC + **lysoDDPB**).



Scheme 1.
Synthesis of di-dabcyI intermediate **4**



Scheme 2.
Synthesis of **DDPB** and **lysoDDPB**